RS58382B1 - Hidrobromidna so n-{4-hloro-2-hidroksi-3-[(3s)-3-piperidinilsulfonil]fenil}-n’-(3-fluoro-2-metilfenil)uree - Google Patents
Hidrobromidna so n-{4-hloro-2-hidroksi-3-[(3s)-3-piperidinilsulfonil]fenil}-n’-(3-fluoro-2-metilfenil)ureeInfo
- Publication number
- RS58382B1 RS58382B1 RS20190230A RSP20190230A RS58382B1 RS 58382 B1 RS58382 B1 RS 58382B1 RS 20190230 A RS20190230 A RS 20190230A RS P20190230 A RSP20190230 A RS P20190230A RS 58382 B1 RS58382 B1 RS 58382B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- disease
- treatment
- cxcr2
- piperidinylsulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1320021.7A GB201320021D0 (en) | 2013-11-13 | 2013-11-13 | Novel Compounds |
| EP14799988.2A EP3068763B1 (en) | 2013-11-13 | 2014-11-11 | Hydrobromide salt of n-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl)-n'-(3-fluoro-2-methylphenyl)urea |
| PCT/EP2014/074222 WO2015071235A1 (en) | 2013-11-13 | 2014-11-11 | Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58382B1 true RS58382B1 (sr) | 2019-04-30 |
Family
ID=49818555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190230A RS58382B1 (sr) | 2013-11-13 | 2014-11-11 | Hidrobromidna so n-{4-hloro-2-hidroksi-3-[(3s)-3-piperidinilsulfonil]fenil}-n’-(3-fluoro-2-metilfenil)uree |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9809540B2 (https=) |
| EP (1) | EP3068763B1 (https=) |
| JP (1) | JP6401265B2 (https=) |
| KR (1) | KR20160083950A (https=) |
| CN (1) | CN105683162A (https=) |
| AU (1) | AU2014350334B2 (https=) |
| BR (1) | BR112016010409A8 (https=) |
| CA (1) | CA2929907A1 (https=) |
| CY (1) | CY1121581T1 (https=) |
| DK (1) | DK3068763T3 (https=) |
| ES (1) | ES2714721T3 (https=) |
| GB (1) | GB201320021D0 (https=) |
| HR (1) | HRP20190449T1 (https=) |
| HU (1) | HUE041873T2 (https=) |
| LT (1) | LT3068763T (https=) |
| ME (1) | ME03328B (https=) |
| PL (1) | PL3068763T3 (https=) |
| PT (1) | PT3068763T (https=) |
| RS (1) | RS58382B1 (https=) |
| RU (1) | RU2685408C1 (https=) |
| SI (1) | SI3068763T1 (https=) |
| SM (1) | SMT201900156T1 (https=) |
| TR (1) | TR201902981T4 (https=) |
| WO (1) | WO2015071235A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170100385A1 (en) * | 2014-05-12 | 2017-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| BR112018011138A2 (pt) * | 2015-11-30 | 2018-11-21 | Glaxosmithkline Intellectual Property (No. | formulações para administração intravenosa |
| WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2009992T3 (pl) * | 2006-04-21 | 2012-11-30 | Glaxosmithkline Llc | Antagoniści receptora IL-8 |
-
2013
- 2013-11-13 GB GBGB1320021.7A patent/GB201320021D0/en not_active Ceased
-
2014
- 2014-11-11 PL PL14799988T patent/PL3068763T3/pl unknown
- 2014-11-11 EP EP14799988.2A patent/EP3068763B1/en active Active
- 2014-11-11 ES ES14799988T patent/ES2714721T3/es active Active
- 2014-11-11 ME MEP-2019-47A patent/ME03328B/me unknown
- 2014-11-11 CA CA2929907A patent/CA2929907A1/en not_active Abandoned
- 2014-11-11 HR HRP20190449TT patent/HRP20190449T1/hr unknown
- 2014-11-11 WO PCT/EP2014/074222 patent/WO2015071235A1/en not_active Ceased
- 2014-11-11 US US15/034,583 patent/US9809540B2/en not_active Expired - Fee Related
- 2014-11-11 TR TR2019/02981T patent/TR201902981T4/tr unknown
- 2014-11-11 DK DK14799988.2T patent/DK3068763T3/en active
- 2014-11-11 AU AU2014350334A patent/AU2014350334B2/en not_active Ceased
- 2014-11-11 RU RU2016116955A patent/RU2685408C1/ru not_active IP Right Cessation
- 2014-11-11 PT PT14799988T patent/PT3068763T/pt unknown
- 2014-11-11 SM SM20190156T patent/SMT201900156T1/it unknown
- 2014-11-11 SI SI201431125T patent/SI3068763T1/sl unknown
- 2014-11-11 HU HUE14799988A patent/HUE041873T2/hu unknown
- 2014-11-11 CN CN201480061455.2A patent/CN105683162A/zh active Pending
- 2014-11-11 BR BR112016010409A patent/BR112016010409A8/pt not_active IP Right Cessation
- 2014-11-11 LT LTEP14799988.2T patent/LT3068763T/lt unknown
- 2014-11-11 JP JP2016529894A patent/JP6401265B2/ja not_active Expired - Fee Related
- 2014-11-11 KR KR1020167015530A patent/KR20160083950A/ko not_active Withdrawn
- 2014-11-11 RS RS20190230A patent/RS58382B1/sr unknown
-
2017
- 2017-10-05 US US15/725,429 patent/US20180079722A1/en not_active Abandoned
-
2018
- 2018-12-13 US US16/218,602 patent/US10604485B2/en not_active Expired - Fee Related
-
2019
- 2019-02-26 CY CY20191100237T patent/CY1121581T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR201902981T4 (tr) | 2019-03-21 |
| US20180079722A1 (en) | 2018-03-22 |
| RU2685408C1 (ru) | 2019-04-18 |
| RU2016116955A (ru) | 2017-12-19 |
| EP3068763A1 (en) | 2016-09-21 |
| LT3068763T (lt) | 2019-03-12 |
| AU2014350334B2 (en) | 2017-08-10 |
| PT3068763T (pt) | 2019-03-20 |
| HRP20190449T1 (hr) | 2019-04-19 |
| CY1121581T1 (el) | 2020-05-29 |
| JP2016537344A (ja) | 2016-12-01 |
| US20190112269A1 (en) | 2019-04-18 |
| GB201320021D0 (en) | 2013-12-25 |
| CN105683162A (zh) | 2016-06-15 |
| US9809540B2 (en) | 2017-11-07 |
| HUE041873T2 (hu) | 2019-05-28 |
| BR112016010409A8 (pt) | 2020-04-22 |
| EP3068763B1 (en) | 2018-12-19 |
| KR20160083950A (ko) | 2016-07-12 |
| SI3068763T1 (sl) | 2019-04-30 |
| ME03328B (me) | 2019-10-20 |
| US10604485B2 (en) | 2020-03-31 |
| CA2929907A1 (en) | 2015-05-21 |
| DK3068763T3 (en) | 2019-03-18 |
| ES2714721T3 (es) | 2019-05-29 |
| PL3068763T3 (pl) | 2019-05-31 |
| WO2015071235A1 (en) | 2015-05-21 |
| SMT201900156T1 (it) | 2019-05-10 |
| JP6401265B2 (ja) | 2018-10-10 |
| AU2014350334A1 (en) | 2016-06-02 |
| US20160264525A1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11945815B2 (en) | PTPN11 inhibitors | |
| CA2915561C (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
| CN101801362B (zh) | 用于治疗病症的方法和组合物 | |
| JP2023029899A (ja) | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 | |
| CN105682655B (zh) | 抗微生物化合物 | |
| EP3681861A1 (en) | Cxcr-2 inhibitors for treating disorders | |
| TW200927129A (en) | Organic compounds | |
| AU2017231832B2 (en) | CXCR-2 inhibitors for treating crystal arthropathy disorders | |
| US10604485B2 (en) | Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea | |
| JP7667764B2 (ja) | 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物 | |
| CN113490512A (zh) | 组合药剂 | |
| CN112839656A (zh) | 急性骨髓性白血病用抗肿瘤剂 | |
| KR20020070525A (ko) | 디아미노트리플루오로메틸피리딘의 유도체를 함유하는소화기 질환 치료제 또는 예방제 | |
| TWI411435B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於治療脊髓創傷之用途 | |
| JP6851489B2 (ja) | 新規エルゴステノールグリコシド誘導体 | |
| JP2023070165A (ja) | アザビシクロ環化合物の結晶 | |
| CN100584330C (zh) | 一种取代苯并咪唑质子泵抑制剂组合物及其制备方法 | |
| WO2026000074A1 (en) | Use of cd38 inhibitors for reducing th2 inflammation | |
| TW201347758A (zh) | 用於類固醇反應性皮膚病的治療方法 | |
| HK40046231A (en) | Antitumor agent for acute myeloid leukemia | |
| HK1260442B (zh) | 用於治疗和预防动物的过敏性和/或炎症性疾病的取代吲唑 | |
| US20140301979A1 (en) | Anti-arenaviral compounds |